Current Position: Home News

Phase 1b Clinical Trial of Next-Generation CTLA-4 Monoclonal Antibody ONC-392 for Gastrointestinal Solid Tumors Officially Launched at Sun Yat-sen University Cancer Center

Time: 2024-08-25 Author: admin_develop Browse: 801

Guangzhou, February 9, 2023 – Under the strong support of Professor Xu Ruihua, President of Sun Yat-sen University Cancer Center, and his team, as well as the close cooperation of collaborating organizations, the Phase 1b clinical trial project “ONC-392 for the Treatment of Liver, Stomach, Esophageal, and Anal Canal Cancers,” sponsored by AcroImmune BioTech Co., Ltd. (Guangzhou), was successfully launched at Sun Yat-sen University Cancer Center. The lead PI, Professor Xu Ruihua, attended the project kick-off meeting and gave a motivational speech. Dr. Shiling Song, Senior Medical Director of AcroImmune, introduced the research background and progress of the project and engaged in active discussions with the research team. Collaborator Tigermed also provided explanations and training on the project procedures. The clinical trial project kick-off meeting was a complete success.

Skip to the Chinese page for details(跳向中文页面 查看详细).